The FAMHP has moved: from 1 March 2021, you will be able to find our departments at the following address.

Federal Agency for Medicines and Health Products - FAMHP
Avenue Galilée 5/03

Map: PNG - PDF

Google Maps


All our telephone numbers and e-mail addresses remain the same.

+32 2 528 40 00 (from 8 AM to 4 PM on working days)

EORI number BE0884579424

Send your questions to the FAMHP by e-mail.
If you don’t know which is the appropriate department send it simply to the general e-mail address at FAMHP: Your question will then be passed on to the relevant department.


Authorisations and certificates

Borderline products whose status is unclear - -

Chief Executive Officer, Xavier De Cuyper - (Secretariat)

Complaints - Complaints about the FAMHP?

Herbal Medicines -

Homeopathic medicines -

Human body material (MCH-MLM) -

Information on the proper use of medicines and health products -

Inspection and control – General -

Inspection and control – Pharmacies -

Inspection and control – Distribution of medicines -

Inspection and control – Industry -

Inspection and control - Medical devices -

Inspection and control – Special Investigation Unit -

Inspection and control - Pharmacovigilance -

Inspection and control - Publicity - General -

Inspection and control - Human Body Material -

Legal Affairs -

Marketing Authorisation - Variations and Renewals -

Medicines for veterinary use -

National Innovation Office -

Narcotics and psychotropics -

Precursors -

Press (For journalists only) -
Ann Eeckhout, spokesperson of the FAMHP
phone +32 2 528 40 12
mobile +32 495 23 71 69

Publicity – Notification and visum -

Research and Development (R&D) -

Scientific-Technical Advice (STA) -

Supply problems and commercialisations -

Vigilance of medicines for human use -

Webmaster -

Medical devices

All current e-mail addresses dedicated to the medical devices and in-vitro diagnostics (IVDs) will be reorganised in order to ensure a better management of the incoming emails and to increase efficiency in processing them.

From the 15th of March 2021, the following e-mail addresses will be phased out and eventually disappear completely:


These general e-mail addresses will be replaced by more specific ones. All new e-mail addresses will be used for enquiries related to medical devices and medical devices for in-vitro diagnostics (IVDs).

For all enquiries about the following topics Contact
- Clinical investigations
- Performance studies
- Serious adverse events
- Scientific-technical advice on innovative devices
- Requests for advice from a Notified Body (Transmissible Spongiform Encephalopathies (TSE)...)
- Notified Bodies and Notified Body certificates (withdrawal, suspension ...)
- Questions related to Notified Bodies
Applications for certificates of free sale and questions related to those certificates
- Compassionate use
- Derogations
- Appeals
All vigilance related documents and questions:
- (serious) incident
- Manufacturer Incident Report (MIR)
- Periodic Summary Report (PSR)
- Field Safety Corrective Action (FSCA)
- Field Safety Notice (FSN)
- Trend report
- Post Market Surveillance (PMS) report
- Periodic Safety Update Report (PSUR) + evaluation
- Breast Implant Associated – Anaplastic Large Cell Lymphoma (BIA-ALCL)
- All security and safety issues with devices
Central traceability register
- Inspection related files
- Advertising and promotion of medical devices
- Self-checking guide (Good distribution practices)
- My control/Self-checking form section on the Portal
- Violations of the medical devices and IVD legislations by registered actors
- Fraud
- Prosecution files
- Violations of the medical device and IVD legislations by non-registered actors
- Marketing and distribution notifications
- Registration of actors
- Business questions related to online applications (except the Autocontrol application)
- Registration in EUDAMED
All technical questions regarding the online applications and the web portal (except EUDAMED)
Technical issues with EUDAMED
The implementation of Regulations (EU) 2017/745 and (EU) 2017/746
- Qualification
- Classification
- Invitations for European/national meetings
- All other enquiries that are not related to topics of the other email boxes
All enquiries about SARS-CoV-2 antigen tests
All enquiries about SARS-CoV-2 serological tests


Last updated on 14/10/2021